Innovative Approaches to Plasminogen Activator Therapy
- 6 January 1989
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 243 (4887) , 51-56
- https://doi.org/10.1126/science.2492113
Abstract
Plasminogen activator therapy for acute myocardial infarction has become standard medical practice. Bleeding complications, however, limit the utility of the currently available agents. This article reviews how the tools of molecular biology and protein engineering are being used to develop safer and more effective plasminogen activators.Keywords
This publication has 49 references indexed in Scilit:
- Thrombolytic Therapy: Current StatusNew England Journal of Medicine, 1988
- Thrombolytic Therapy: Current StatusNew England Journal of Medicine, 1988
- Effect of Intravenous Streptokinase on Left Ventricular Function and Early Survival after Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- A Randomized Trial of Immediate versus Delayed Elective Angioplasty after Intravenous Tissue Plasminogen Activator in Acute Myocardial InfarctionNew England Journal of Medicine, 1987
- Preclinical Pharmacological Evaluation of Anisoylated Plasminogen Streptokinase Activator ComplexDrugs, 1987
- A Prospective Trial of Intravenous Streptokinase in Acute Myocardial Infarction (I.S.A.M.)New England Journal of Medicine, 1986
- Intravenous streptokinase in acute myocardial infarction: Experience of community hospitals served by paramedicsAmerican Heart Journal, 1986
- Covalent molecular weight .apprx. 92,000 hybrid plasminogen activator derived from human plasmin amino-terminal and urokinase carboxyl-terminal domainsBiochemistry, 1986
- Functional analysis of the human tissue-type plasminogen activator protein: the light chainGene, 1986
- Prevalence of Total Coronary Occlusion during the Early Hours of Transmural Myocardial InfarctionNew England Journal of Medicine, 1980